Evommune is a clinical-stage biotechnology company developing therapies that target key drivers of chronic immune-mediated inflammation. Early clinical programs address chronic spontaneous urticaria, atopic dermatitis and ulcerative colitis with candidates such as EVO756 and EVO301. The focus is on improving day-to-day disease control and reducing long-term damage from uncontrolled inflammation where existing options fall short.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q4 2024 | 0 | — | -22.2 | — |
| Q3 2025 | 10 | — | -12.5 | — |
| Q4 2025 | 0 | — | -28.3 | — |
| Q1 2026 | 0 | — | -21.7 | — |
| Q2 2026 | 0 | — | -32.3 | — |
All markets — KeepWinning global stock screener
Other companies on NYSE: Apollo Commercial Real Estate Finance, Inc. (ARI), Regional Management Corp. (RM), BlackRock Floating Rate Income Trust (BGT), Alpine Income Property Trust, Inc. (PINE), CH4 Natural Solutions Corporation (MTNE), KPET Ultra Paceline Corporation (KPET)